BartDay
  • Economy
    • Business
    • Politics
  • Cryptocurrency
  • Investing
    • Banking
    • Forex
    • Financial Services
  • Markets
    • Capital Markets
    • Emerging Markets
  • People
    • Consumer & Retail
    • Health
    • Opinion
  • Environment
    • Energy
    • Industrials
    • Manufacturing
  • Technology
    • Learning
    • Auto & Transportation
    • Data
    • Science
    • Telecommunications
  • Featured
  • About
  • Economy
    • Business
    • Politics
  • Cryptocurrency
  • Investing
    • Banking
    • Forex
    • Financial Services
  • Markets
    • Capital Markets
    • Emerging Markets
  • People
    • Consumer & Retail
    • Health
    • Opinion
  • Environment
    • Energy
    • Industrials
    • Manufacturing
  • Technology
    • Learning
    • Auto & Transportation
    • Data
    • Science
    • Telecommunications
  • Featured
  • About
BartDay
BartDay
  • Economy
    • Business
    • Politics
  • Cryptocurrency
  • Investing
    • Banking
    • Forex
    • Financial Services
  • Markets
    • Capital Markets
    • Emerging Markets
  • People
    • Consumer & Retail
    • Health
    • Opinion
  • Environment
    • Energy
    • Industrials
    • Manufacturing
  • Technology
    • Learning
    • Auto & Transportation
    • Data
    • Science
    • Telecommunications
  • Featured
  • About

Pfizer, BioNTech: COVID-19 Vaccine Candidate More Than 90% Effective

  • November 9, 2020
  • 2 minute read
Total
0
Shares
0
0
0
0

Pharmaceutical giant Pfizer Inc. (PFE) and German biotech firm BioNTech SE (BNTX) said Monday that their coronavirus vaccine candidate, BNT162b2, was found to be more than 90 percent effective in preventing COVID-19 among patients without prior evidence of infection.

Following the news, shares of Pfizer are rising almost 16 percent or $5.75 in pre-market trade to $42.15.


Partner with bartday.com. Kindly head here.


From our partners:

CITI.IO :: Business. Institutions. Society. Global Political Economy.
CYBERPOGO.COM :: For the Arts, Sciences, and Technology.
DADAHACKS.COM :: Parenting For The Rest Of Us.
ZEDISTA.COM :: Entertainment. Sports. Culture. Escape.
TAKUMAKU.COM :: For The Hearth And Home.
ASTER.CLOUD :: From The Cloud And Beyond.
LIWAIWAI.COM :: Intelligence, Inside and Outside.
GLOBALCLOUDPLATFORMS.COM :: For The World's Computing Needs.
FIREGULAMAN.COM :: For The Fire In The Belly Of The Coder.
ASTERCASTER.COM :: Supra Astra. Beyond The Stars.
BARTDAY.COM :: Prosperity For Everyone.


The results were based on the first interim efficacy analysis conducted by an external, independent Data Monitoring Committee or DMC from the vaccine’s Phase 3 clinical study.

According to Pfizer and BioNTech, their mRNA-based vaccine candidate, BNT162b2, was found to be effective against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO.

The results comes as coronavirus cases continue to surge worldwide and economies struggle to reopen.

The late-stage clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date. Of the total participants, 38,955 have received a second dose of the vaccine candidate as of November 8, 2020.

The trial continues to enroll participants and is expected to continue through the final analysis, when a total of 164 confirmed COVID-19 cases have accrued. The interim analysis by DMC evaluated 94 confirmed COVID-19 infections among the trial’s participants.

The comparison of data between vaccinated individuals and those who received the placebo indicated a vaccine efficacy rate above 90 percent, seven days after the second dose was given. This means that protection from COVID-19 is achieved 28 days after the initiation of the vaccination, which consists of a two-dose schedule.

The DMC did not report any serious safety concerns and has recommended that the study continue to collect additional safety and efficacy data as planned.

The Phase 3 study will also evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease.

The companies plan to submit for emergency use authorization to the FDA after accumulating two months of safety data, which is expected to be available by the third week of November.

Based on current projections, Pfizer and BioNTech expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

For comments and feedback contact: [email protected]

Business News

BartDay

Related Topics
  • BioNTech
  • coronavirus
  • COVID-19
  • Pfizer
  • Vaccine
You May Also Like
college-of-cardinals-2025
Read More
  • 1 min
  • Featured

The Definitive Who’s Who of the 2025 Papal Conclave

  • May 7, 2025
conclave-poster-black-smoke
Read More
  • 4 min
  • Featured
  • World Events

The World Is Revalidating Itself

  • May 6, 2025
Read More
  • 1 min
  • Featured
  • People

Conclave: How A New Pope Is Chosen

  • April 25, 2025
Read More
  • 4 min
  • Featured
  • World Events

Tariffs, Trump, and Other Things That Start With T – They’re Not The Problem, It’s How We Use Them

  • March 25, 2025
zedreviews-Apple-iPhone-16-Pro-finish-lineup-240909
Read More
  • 12 min
  • Featured
  • Gears
  • Technology

Apple debuts iPhone 16 Pro and iPhone 16 Pro Max

  • September 10, 2024
zedreviews-Apple-iPhone-16-Apple-Intelligence-240909
Read More
  • 12 min
  • Featured
  • Gears
  • Technology

Apple introduces iPhone 16 and iPhone 16 Plus

  • September 10, 2024
zedreviews-Apple-AirPods-Active-Noise-Cancellation-240909
Read More
  • 8 min
  • Featured
  • Gears
  • Technology

Apple introduces AirPods 4 and the world’s first all-in-one hearing health experience with AirPods Pro 2

  • September 10, 2024
zedreviews-Apple-health-2-up-240909
Read More
  • 9 min
  • Featured
  • Gears
  • Technology

Apple introduces groundbreaking health features to support conditions impacting billions of people

  • September 10, 2024
  • Smart Watch
    Best Smartwatches, Your Gateway to Health Monitoring and Everyday Use
    • October 4, 2025
  • IBM, ESPN Fantasy Football
    New IBM watsonx AI-Powered Insights Help Elevate ESPN Fantasy Football for 2025 Fantasy Football Season
    • September 27, 2025
  • Cooking pots and pans
    Best Pots and Pans 2025: All-Season, All-Purpose Picks for Every Kitchen
    • September 22, 2025
  • Kitchen Knives - Best All-Around Picks in 2025
    Kitchen Knives : The Surgeons of Cooking – Best All-Around Picks in 2025
    • September 14, 2025
  • NVIDIA Blackwell Ultra Sets the Bar in New MLPerf Inference Benchmark
    • September 9, 2025
about
Unleash Your Financial Potential With Us

BartDay is your all-in source of information for market insights, finance news, investing, trading, and more.

Data and information is provided “as is”. BartDay and any of its information service providers or third party sources is not liable for loss of revenues or profits and damages.

For comments, suggestions, or sponsorships, you may reach us at [email protected]
  • Smart Watch 1
    Best Smartwatches, Your Gateway to Health Monitoring and Everyday Use
    • October 4, 2025
  • IBM, ESPN Fantasy Football 2
    New IBM watsonx AI-Powered Insights Help Elevate ESPN Fantasy Football for 2025 Fantasy Football Season
    • September 27, 2025
  • Cooking pots and pans 3
    Best Pots and Pans 2025: All-Season, All-Purpose Picks for Every Kitchen
    • September 22, 2025
  • Kitchen Knives - Best All-Around Picks in 2025 4
    Kitchen Knives : The Surgeons of Cooking – Best All-Around Picks in 2025
    • September 14, 2025
  • 5
    NVIDIA Blackwell Ultra Sets the Bar in New MLPerf Inference Benchmark
    • September 9, 2025
BartDay
  • Economy
  • Cryptocurrency
  • Investing
  • Markets
  • People
  • Environment
  • Technology
  • Featured
  • About
Unleash Your Financial Potential With Us

Input your search keywords and press Enter.